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ABSTRACT. Prior to the 1999 New York City outbreak few had ever heard of West Nile virus. That changed
rapidly once the illness caused by the virus resulted in deaths, hospitalizations, and early fears of the
unknown etiology of the disease. In some ways it was like Legionnaire's Disease all over again. This
review, although not extensive, will cover many of the medical, biological, epidemiological, diagnostic,
and public health considerations regarding this new entry onto the list of disease agents seen in the
United States.
It is important that each of us is knowledgeable regarding new scientific information. It is all too easy
for misinformation to be disseminated to the public by news media and word of mouth. Scientific societies
must be ready to protect the public from this misinformation and to add perspective to the issue.
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INTRODUCTION
The purpose of this review is to provide the member-
ship of the Ohio Academy of Science who may be un-
familiar with the biological, clinical, and preventive
aspects of West Nile virus (WNV) and its infectious
process in humans, information that will be both inter-
esting and useful.
Isolation of WNV first occurred in 1937 from an
infected person living in the West Nile area of Uganda
(Smithburn and others 1940). Since that time, outbreaks
have occurred in endemic areas that include Africa, the
Middle East, southern Europe, southwest and central
Asia, and Oceania (Mandell and others 2000). The virus
is most commonly transmitted by mosquitoes of the
genus Culex (Brooks and others 2001). After being bitten
by an infected female mosquito, the virus spreads
throughout the body of the human host. If symptoms
appear they are typically an acute, usually mild febrile
disease often accompanied by malaise, anorexia, nausea,
vomiting, and headache (Table 1). Transient meningeal
involvement may occur at this time. Fatal cases asso-
ciated with severe neurological manifestations have
been seen in the elderly or debilitated person (Table 2).
Until 1999, this was our understanding of West Nile
virus and the associated infection. At that time the virus
caused an outbreak in New York City (Nash and others
2001). It should not be surprising that since 1999, our
knowledge of West Nile virus has increased as the virus
has spread across the country.
WHAT IS WEST NILE VIRUS?
West Nile fever is caused by an arbovirus of the
family Flaviviridae and the genus Flavivirus (Brooks and
others 2001). The virus is commonly called West Nile
virus. The virus is spherical, with a diameter of about
50.0 nm. The nucleic acid is single-stranded RNA with a
positive sense (that is, the viral RNA acts like a messenger
RNA in host cells). The virus has a viral hemagglutinin
TABLE 1
Signs and symptoms during the West Nile virus
epidemic, New York City, 1999*.
Sign/Symptom Percent Cases Observed
Fever
Weakness
Nausea
Vomiting
Headaches
Confusion
Diarrhea
Rash
90
56
53
51
47
46
27
19
Manuscript received 15 October 2002 and in revised form 18
November 2002 (#02-20).
*Per Nash D and others 2001.
(E-glycoprotein) that is involved in host cell attachment.
This hemagglutinin can stimulate neutralizing anti-
bodies (Mandell and others 2000; Petersen and Marfin
2002).
WNV is closely related antigenically with Japanese
encephalitis and St. Louis encephalitis. This can lead to
laboratory misdiagnoses (discussed later). The virus, like
other Flaviviridae viruses, replicates in the host cell's
cytoplasm and virus particles assemble at the host's en-
doplasmic reticulum. Once whole virus is assembled,
infection can spread to other cells of the host.
THE EN2OOTIC CYCLE
The reservoir of the virus appears to be within various
bird populations. In the United States this reservoir
seems to be most extensive in crows, although other
birds such as Blue Jays have been implicated (MMWR
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TABLE 2
Clinical presentations and laboratory values for hospitalized patients. West Nile virus encephalitis—New York, City epidemic, 1999*.
Clinical Characteristics of Presenting Patients
Incubation period: 3-15 clays
Subclinical: 99%
Disease: Encephalitis with profound muscle weakness
Mortality: Approx. 10% (age >75)
Disease Risks: Elderly, Diabetes, Outdoor Activity
Syndromes**
Encephalitis with Weakness
Encephalitis without Weakness
Aseptic Meningitis
Fever and Headache
Percent of Patients Presenting*
34.0
29.0
29.0
8.0
Laboratory Study**
Cerebrospinal Fluid
Protein
WBC
Lymphocytes
Glucose
Peripheral White Blood Cells
Laboratory Value (Mean)**
104 (15-45 mg/100 ml***)
38 (0-10/cu mm***)
47% (0.0%**)
79.8 (45-80 mg/dl***)
10,400 (4,500-10,500/cc)
*Per Nash D and others 2001. **N = 59 patients hospitalized. "•Normal Values Per Wallach J 1981.
2002a; O'Leary and others 2002). Most birds develop
immunity once infected and rarely die from the illness.
A number of other vertebrates can be infected with
WNV, including chickens and horses (MMWR 2002b), as
well as humans. Direct animal-to-human or human-to-
human transmissions have not been well documented,
except in rare transplant situations (MMWR 2002d) and,
possibly, in mother's milk (MMWR 2002e). With the ex-
ception of birds, infection of other hosts appears to be
coincidental.
The enzootic cycle is relatively straightforward. During
the spring and summer months, female Culex sp. of
mosquitoes take a blood meal from an infected verte-
brate host, usually a bird. After picking up the virus they
can readily transmit the virus to a susceptible host at the
next blood meal. Other genera of mosquitoes and in-
sects (sand flies and ticks) may also act as vectors (Turell
and others 2001). Although mosquitoes tend to be
somewhat species-specific regarding blood meals, they
can become more cosmopolitan under certain cir-
cumstances. When humans become the incidental blood
source for infected mosquitoes and so become in-
fected, the outbreak gets our attention. The "bird(or
other host)-to-mosquito" cycle seems to continue through-
out the spring and summer months, ending as the weather
gets cold and mosquito activity ceases. How the virus
over-winters has been open to discussion. Studies of birds
along the usual eastern and midwestern north-south
flyways appear to indicate that birds carry the virus to
warmer climates over the winter months (O'Leary and
others 2002). The virus has been detected in birds as
far north as Canada and as far south as the Caribbean.
THE US EXPERIENCE
In late August of 1999, a number of cases of en-
cephalitis were detected in the New York City borough
of Queens (Table 2). An excellent job of public health,
medical diagnosis, and environmental epidemiology
eventually resulted in isolation and identification of
West Nile virus from persons who contracted the dis-
ease and also from animal sources (Lopez 2002). From
that time until now, WNV has spread throughout much
of the United States. It is interesting to note that isolates
from the US appear to be strongly related, genetically, to
isolates from Israel that were prominent there from 1997
to 2000 (Giladi and others 2001). The relationship of the
two sets of isolates was approximately 99-8% using re-
verse transcription-polymerase chain reaction data.
Whether this Israeli homolog was the source of the virus
that appeared in the US in 1999 is unknown. (This
homolog appears elsewhere in the Middle East as well,
but rarely is epidemiological testing done in the area.)
Also unknown is how the virus got into the United States.
Another interesting aspect of the US isolates is that
although they cause the same symptoms as any classical
case of West Nile from the original endemic areas in
Africa, Asia, the Middle East and Europe, there seems to
be a slightly higher morbidity rate, although death is still
very uncommon (Mostashari and others 2001). From 1
January to 4 October 2002 there have been a total of
2,631 laboratory-confirmed cases of WNV infection re-
ported to the Centers for Disease Control and Prevention
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(CDC 2002b). Of this group, there were 136 deaths at-
tributed to West Nile. Thus the apparent death rate is 52
deaths per 1000 clinical cases for all ages. Death rates
approaching 200 deaths per 1000 clinical cases are not
uncommon in the population over 70 years of age
(Petersen and Marfin 2002). Most cases go undiagnosed,
so that the above statistics are skewed.
CLINICAL MANIFESTATIONS
The incubation period for West Nile is 3 to 15 days
after infection of the human host. Most patients in-
fected with WNV are asymptomatic and therefore have
no clinical evidence of disease (Table 2). Symptoms
appear in about 20% of those infected and usually last
3 to 6 days. These usually appear as the mild form of
the infection—West Nile fever. Persons with West Nile
fever usually present with a sudden onset of some or
all of the following symptoms: anorexia, eye pain, head-
ache, lymphadenopathy, nausea and/or vomiting, malaise,
and myalgia (Mostashari and others 2001). The frequency
of various symptoms and signs associated with WNV
from the New York outbreak is shown in Table 1. More
than 90% of patients hospitalized during this outbreak
had fever. Nausea, vomiting, and headache were also
common during this outbreak. A skin rash was evident
in a minority of patients and was usually described as
erythematous, macular, or morbilliform in nature. Only
about one person in 150 cases will get the severe neuro-
logic disease. This is about 0.7% of cases. Thus, if 71
deaths have indeed occurred from 1,571 confirmed
cases of West Nile infection, a large number of people
(50,000 to 100,000 persons) have actually been infected,
but with inapparent or no symptoms. Advanced age,
especially over 70 years of age, is still the most common
risk factor in cases of death from West Nile infection
(Nash and others 2001).
A small number of patients have presented with an
acute flaccid paralysis associated with a peripheral
demyelinating process (Guillain-Barre Syndrome)
(MMWR 2002c). The exact etiology of this process has not
been well investigated. Research that has been done thus
far suggests that the acute flaccid paralysis involves the
anterior horn cells of the spinal cord and motor axons,
not unlike that seen with acute poliomyelitis (Ohry and
others 2001). The appearance of a polio-like syndrome
has been reported for other flavivirus infections as well
(Solomon and others 1998).
Another recent development regarding WNV has been
the appearance of the agent in organ donor tissue
(MMWR 2002c) transplanted into recipients and in trans-
fusion recipients. These situations are currently under
public health scrutiny and are rather worrisome. At
least four persons received transplanted tissue from
one WNV infected donor. One of these recipients died
of WNV disease and the others appear to be recovering.
The CDC has reports of patients receiving blood products
that may have been infected with WNV (MMWR 2002c).
There are two viruses that are somewhat similar to
WNV, and should be mentioned at this time. St. Louis
encephalitis (SLE) is very similar to WNV in that it is in the
same family as WSN (Flaviviridae) and causes similar
symptoms. The vector (Culex mosquitoes) and the
reservoirs are similar to WNV. About 125 cases of SLE
are reported per year. Although outbreaks of SLE occur
throughout the United States, most occur in the Mid-
west and South (CDC 2002c). WNV and SLE can be
differentiated through serological testing. The second
virus that is similar to WNV is La Crosse encephalitis
(LCE). However, LCE is a member of the family
Bunyaviridae. This family differs structurally, antigeni-
cally, and in the way it replicates from the Flaviviridae.
LCE causes outbreaks of encephalitis most commonly
in the Mississippi and Ohio River valleys (CDC 2002d).
The vector is usually woodland mosquitoes (for ex-
ample, Aedes spp.). Small mammals, such as squirrels,
chip-munks and rabbits, are the reservoir. As such, most
outbreaks are not urban in nature but rural. Only about
100 cases are reported each year and most of these in
persons under 20 years of age. Interestingly, La Crosse
is related to the Hantavirus group. WNV and LCE differ
serologically.
DIAGNOSIS, TREATMENT,
AND PREVENTION
Diagnosis is initially made by identification of symp-
toms and confirmed by laboratory workup. Laboratory
diagnosis consists of tests to detect antibodies against
virus or viral nucleic acid in serum and/or spinal fluid.
The optimal serologic method to detect these antibodies
is an IgM antibody capture enzyme-linked immuno-
sorbent assay (MAC-ELISA). Persons infected less than 8
days prior to the test may not be positive. Persons with
a prior exposure (within about six months) to WNV
may also be positive, as well as those vaccinated for
or infected with a different flavivirus, such as yellow
fever, Japanese encephalitis, or dengue. A plaque re-
duction neutralization test may be useful in identifying
false-positive MAC-ELISA test specimens (Martin 2002).
Results of nucleic acid amplification (PCR) testing have
been positive in up to 55% of CSF samples and in 10%
of serum samples from patients with WNV (NYDH
2001). The CDC may perform a plaque reduction neu-
tralization test (PRNT) on specimens under certain
conditions, to assist in a confirmatory diagnosis (CDC
2002a). Persons who present with a four-fold increase
in acute versus convalescent serum titers of antibody
against WNV antigen are considered confirmed cases
(CDC 2002e).
There is as yet no documented effective direct treat-
ment for this virus—not unlike many viral infections.
Treatment generally is supportive care; however, inter-
feron alpha-2b and ribavirin have been suggested as a
possible treatment in severe cases of West Nile en-
cephalitis (Anderson and Rahal 2002). At this time there is
no controlled study data to support the use of these
agents. There is no vaccine currently available for
human use. A vaccine does exist for horses, which are
especially susceptible to West Nile infection, with a 40%
mortality rate in cases where symptoms occur. Even so,
most horses do recover. Other vaccines for various
forms of equine encephalitis (for horses) do not protect
from West Nile infection.
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Obviously the best "treatment" is to never come in
contact with an infected mosquito. To accomplish this,
one needs to take personal care to use insect repellents
(Fradin 1998) and avoid the mosquito vector's habitat—
regions near standing bodies of water. In a recent
article, Fradin and Day (2002) indicate that DEET-based
repellents may be superior to other repellents in re-
pelling mosquitoes that carry WNV. In another article
by Pollack and others (2002), the authors specifically
caution against the use of botanical repellents and certain
devices marketed as insect repellents or attractants. Use
of screens in windows and use of clothing covering the
body when outside are helpful in preventing insect
bites, especially when used with appropriate repellents.
Persons should watch the time of day they plan activ-
ities. Early morning or late evening activities should be
avoided because of high mosquito activity at those
times. Area Public Health Departments usually include
periodical spraying for insects and, when possible, use of
larvicides. Homeowners can assist by spraying appro-
priately when insects become numerous in their yards
and by removing potential mosquito breeding areas
such as standing water or old tires where standing water
can accumulate.
AFTERWORD
Although West Nile is a new, interesting, and indeed
clinically important consideration, its impact should not
be over-emphasized. When people die from an infection,
it is a concern to all. However, the death rates due to
infections from this organism have been relatively low
when compared to such viral infections as influenza.
While it is certainly important to direct attention to
WNV, we must not reduce our efforts to encourage
appropriate immunizations for other serious infections.
The national media tends to exaggerate and over-
emphasize new diseases and infections (Anonymous
2002). It is up to members of scientific societies to give
perspective to news accounts of such situations. Mem-
bers of the Ohio Academy of Science should provide
such perspective when needed.
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